These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 15489090)

  • 21. Renal function, concomitant medication use and outcomes following acute coronary syndromes.
    Reddan DN; Szczech L; Bhapkar MV; Moliterno DJ; Califf RM; Ohman EM; Berger PB; Hochman JS; Van de Werf F; Harrington RA; Newby LK
    Nephrol Dial Transplant; 2005 Oct; 20(10):2105-12. PubMed ID: 16030030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of beta-blocker therapy on mortality rates and future myocardial infarction rates in patients with coronary artery disease but no history of myocardial infarction or congestive heart failure.
    Bunch TJ; Muhlestein JB; Bair TL; Renlund DG; Lappé DL; Jensen KR; Horne BD; Carter MA; Anderson JL;
    Am J Cardiol; 2005 Apr; 95(7):827-31. PubMed ID: 15781009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.
    Brugts JJ; Boersma E; Chonchol M; Deckers JW; Bertrand M; Remme WJ; Ferrari R; Fox K; Simoons ML;
    J Am Coll Cardiol; 2007 Nov; 50(22):2148-55. PubMed ID: 18036453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
    Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy.
    Dhaliwal AS; Bredikis A; Habib G; Carabello BA; Ramasubbu K; Bozkurt B
    Am J Cardiol; 2008 Nov; 102(10):1356-60. PubMed ID: 18993155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure.
    Horwich TB; MacLellan WR; Fonarow GC
    J Am Coll Cardiol; 2004 Feb; 43(4):642-8. PubMed ID: 14975476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial.
    Solomon SD; Rice MM; A Jablonski K; Jose P; Domanski M; Sabatine M; Gersh BJ; Rouleau J; Pfeffer MA; Braunwald E;
    Circulation; 2006 Jul; 114(1):26-31. PubMed ID: 16801465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High mortality associated with precluded coronary artery bypass surgery caused by severe distal coronary artery disease.
    Rocha AS; Dassa NP; Pittella FJ; Barbosa ON; Brito JO; Tura B; Silva PR
    Circulation; 2005 Aug; 112(9 Suppl):I328-31. PubMed ID: 16159841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study.
    Blackburn DF; Dobson RT; Blackburn JL; Wilson TW; Stang MR; Semchuk WM
    Can J Cardiol; 2005 May; 21(6):485-8. PubMed ID: 15917876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The determination of the factors impacting on in-hospital mortality in patients with acute heart failure in a tertiary referral center].
    Zoghi M; Duygu H; Güngör H; Nalbantgil S; Yilmaz GM; Tülüce K; Ozerkan F; Akilli A; Akin M
    Anadolu Kardiyol Derg; 2008 Aug; 8(4):255-9. PubMed ID: 18676300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease.
    Allen LaPointe NM; Zhou Y; Stafford JA; Hernandez AF; Kramer JM; Anstrom KJ
    Am J Cardiol; 2009 Jun; 103(11):1518-24. PubMed ID: 19463509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation.
    Nieuwlaat R; Eurlings LW; Cleland JG; Cobbe SM; Vardas PE; Capucci A; López-Sendòn JL; Meeder JG; Pinto YM; Crijns HJ
    J Am Coll Cardiol; 2009 May; 53(18):1690-8. PubMed ID: 19406345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart.
    Anselmino M; Malmberg K; Ohrvik J; Rydén L;
    Eur J Cardiovasc Prev Rehabil; 2008 Apr; 15(2):216-23. PubMed ID: 18391651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacotherapy in patients with stable coronary artery disease treated on an outpatient basis in Poland. Results of the multicentre RECENT study.
    Banasiak W; Wilkins A; Pociupany R; Ponikowski P
    Kardiol Pol; 2008 Jun; 66(6):642-9; discussion 650. PubMed ID: 18626833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.
    Go AS; Yang J; Ackerson LM; Lepper K; Robbins S; Massie BM; Shlipak MG
    Circulation; 2006 Jun; 113(23):2713-23. PubMed ID: 16754803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of blood pressure and its evolving changes with the survival of patients with heart failure.
    Grigorian-Shamagian L; Gonzalez-JuAnatey JR; Vazquez R; Cinca J; Bayes-Genis A; Pascual D; Fernandez-Palomeque C; Bardaji A; Almendral J; Nieto V; Macaya C; Jimenez RP; de Luna AB;
    J Card Fail; 2008 Sep; 14(7):561-8. PubMed ID: 18722321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment practices in heart failure with preserved left ventricular ejection fraction: a prospective observational study.
    Peltier M; Houpe D; Cohen-Solal A; Béguin M; Levy F; Tribouilloy C
    Int J Cardiol; 2007 Jun; 118(3):363-9. PubMed ID: 17049391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).
    van Veldhuisen DJ; Cohen-Solal A; Böhm M; Anker SD; Babalis D; Roughton M; Coats AJ; Poole-Wilson PA; Flather MD;
    J Am Coll Cardiol; 2009 Jun; 53(23):2150-8. PubMed ID: 19497441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neither diabetes nor glucose-lowering drugs are associated with mortality after noncardiac surgery in patients with coronary artery disease or heart failure.
    Hanninen M; McAlister FA; Bakal JA; van Diepen S; Ezekowitz JA
    Can J Cardiol; 2013 Apr; 29(4):423-8. PubMed ID: 22985785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency.
    Tonelli M; Bohm C; Pandeya S; Gill J; Levin A; Kiberd BA
    Am J Kidney Dis; 2001 Mar; 37(3):484-9. PubMed ID: 11228171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.